OM
publications
22
first author
10
median RCR
0.60
citations
125
more attributed publications than 98% of the 617 current internal medicine residents in the corpus
Publications
- 2026Therapeutic Benefit Ratings for FDA Breakthrough-Designated Devices.JAMA surgery0 citesPMID 41739483
- 2026Medical Device Regulation - Who Does the FDA Serve?JOURNAL OF LAW MEDICINE & ETHICSfirst author0 citesPMID 41879133
- 2025Research Derived From Medicare's Coverage With Evidence Development Program.JAMA network open0 citesPMID 40232723
- 2025Hospital Acquisition Costs for Breakthrough-Designated Devices Awarded Supplemental Medicare Reimbursement.JAMA health forumfirst author1 citesPMID 41296375
- 2025Voting Trends Among Otolaryngology-Head and Neck Surgery Trainees.Laryngoscope investigative otolaryngology0 citesPMID 39990818
- 2025Characterization of studies considered and required under Medicare's coverage with evidence development program.Clinical trials (London, England)0 citesPMID 39921418
- 2025Assessing Medicare's Coverage With Evidence Development Program.Health affairs (Project Hope)1 citesPMID 39761464
- 2024Medical Devices Applying for Outpatient Medicare Supplemental Payments.JAMA health forumfirst authorRCR 0.351 citesPMID 39546305
- 2024Medicare Local Coverage Determinations: Evidence Quality Is Stronger For Covered Indications.Health affairs (Project Hope)first authorRCR 0.131 citesPMID 39626147
- 2024Regulation and Payment of New Medical Technologies (Yale University dissertation)first author
- 2024HPR109 Evaluation of Evidence Informing Medicare's Coverage With Evidence Development Decision Updates
- 2023Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices Program.JAMA cardiologyfirst authorRCR 1.5314 citesPMID 37878306
- 2022Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.BMJ (Clinical research ed.)first authorRCR 2.5021 citesPMID 35537738
- 2022New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence.Drug safetyfirst authorRCR 1.3115 citesPMID 35182362
- 2022Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016.JAMA internal medicineRCR 0.6010 citesPMID 36190713
- 2022Generating evidence during a pandemic: what's reliable?BMJ (Clinical research ed.)RCR 0.000 citesPMID 35577370
- 2021An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19.Health affairs (Project Hope)RCR 1.6130 citesPMID 33211535
- 2021Direct-to-consumer personal genomic tests need better regulation.Nature medicinefirst authorRCR 0.264 citesPMID 34017136
- 2021Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020JAMA Network Openfirst authorRCR 0.112 citesPMID 33929526
- 2020Covid-19, Single-Sourced Diagnostic Tests, and Innovation PolicyJournal of Law and the BiosciencesRCR 0.123 citesPMID 32908672
- 2017Electrostatic Screening of Charged Defects in Monolayer MoS<sub>2</sub>JOURNAL OF PHYSICAL CHEMISTRY LETTERSRCR 0.7822 citesPMID 28448150
- 2017Electrostatic Screening of Charged Defects in 2D Materials
Compiled from public program rosters and open scholarly data (PubMed, OpenAlex, ORCID) with field-normalized impact (NIH iCite RCR). Publication attribution is being actively improved; counts shown are conservative.